SCHEMBL22190920

SCHEMBL22190920

O=c1[nH]c2ccc(-c3cnc(NCc4ccccc4F)nc3)cc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 7/20 0.64
▸ MAPT P10636 6/20 0.64
▸ VNN1 O95497 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ DYRK1A Q13627 1/20 0.46
▸ LMNA P02545 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ THRB P10828 1/20 0.43
▸ MKNK2 Q9HBH9 2/20 0.42
▸ PLK4 O00444 1/20 0.42
▸ CHEK1 O14757 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ MAP4K4 O95819 1/20 0.42
▸ CDK1 P06493 1/20 0.42
▸ LYN P07948 1/20 0.42
▸ RET P07949 1/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ FER P16591 1/20 0.42
▸ CDK2 P24941 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22190817 0.86 GAA (0.54) GAAMAPTVNN1L3MBTL1DYRK1A
SCHEMBL22191264 0.84 DYRK1A (0.48) GAAMAPTDYRK1ALMNAMEN1
SCHEMBL29437806 0.84 DYRK1A (0.48) GAAMAPTDYRK1ALMNAMEN1
SCHEMBL22191095 0.84 PLK4 (0.50) GAAMAPTVNN1DYRK1AKMT2A
SCHEMBL22191402 0.83 GAA (0.67) GAAMAPTL3MBTL1DYRK1ALMNA
SCHEMBL22191321 0.82 DYRK1A (0.48) GAAMAPTDYRK1AMEN1KMT2A
SCHEMBL29437817 0.82 MKNK2 (0.44) GAAMAPTVNN1L3MBTL1DYRK1A
SCHEMBL22190998 0.81 GAA (0.47) GAAMAPTVNN1L3MBTL1DYRK1A
SCHEMBL28644765 0.81 PLK4 (0.55) GAAMAPTVNN1MEN1KMT2A
SCHEMBL22190930 0.81 AURKB (0.44) GAAMAPTDYRK1AMKNK2PLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-03 — — US disclosed
EP-3906028-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE Icahn School of Medicine at Mount Sinai (US) 2021-11-10 — — EP disclosed
CN-113543783-A Kinase inhibitor compounds and compositions and methods of use 西奈山伊坎医学院 2021-10-22 — — CN disclosed
WO-2020142486-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2020-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220064146-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE CSNK1A1, MAP3K20, CSNK1G3 GAA 1058/4885MAPT 1414/4885VNN1 4064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback